Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics
The new area includes a recording of the webcast and Question & Answer session, which was held for interested parties, including shareholders, on 24 November. During the webcast, shareholders were provided with a more-detailed presentation of the proposed merger with APIM and were given the opportunity to ask their specific questions regarding the merger plans.
Malene Brondberg, Interim CEO and CFO of
The proposed merger, which is backed by the Boards of Directors of both companies, is the result of an extensive review conducted by
After evaluating 25 possible merger and acquisition opportunities, the Company determined that the merger transaction with APIM represents the best and most exciting opportunity for all of
How to register for the general meeting
Shareholders wishing to attend the general meeting must register no later than
Electronic registration of attendance, proxies and advance voting is easily available through the link posted at the Company's website: www.nordicnanovector.com. An individual ref. no. and PIN-code required to access the service have been sent to all shareholders with known address.
Registration of personal attendance and proxies can also be made by mail to Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107
The form of registration of attendance (in person or by proxy) is attached with the notice as made available on
Advokatfirmaet Schjødt AS is acting as legal advisor to APIM. The valuation of
Jan H. Egberts, Chairman of
Malene Brondberg, Interim CEO and CFO of
+ 44 7561 431 762
International Media -
+44 203 928 6900
+47 916 10 911
- Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma (NHL);
- Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukaemia;
- Multiple fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases; and
- A CD37
DOTA CAR-Tcell opportunity in haematological cancers, which is being advanced via a research collaboration with the University of Pennsylvania.
Further information can be found at www.nordicnanovector.com.
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.
Matters discussed in this announcement constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions. Although
The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice.
This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities.
View original content:https://www.prnewswire.co.uk/news-releases/nordic-nanovector-launches-dedicated-area-on-its-website-in-norwegian-for-information-on-the-proposed-merger-with-apim-therapeutics-301687207.html